NCT03755739View on ClinicalTrials.gov

Trans-Artery/Intra-Tumor Infusion of Checkpoint Inhibitors Plus Chemodrug for Immunotherapy of Advanced Solid Tumors

PHASE2/PHASE3RecruitingINTERVENTIONAL
Enrollment

200

Participants

Timeline

Start Date

November 1, 2018

Primary Completion Date

November 1, 2033

Study Completion Date

November 1, 2036

Conditions
HepatocarcinomaLung CancerMelanomaRenal CancerHead and Neck CancerPancreas CancerOvarian CancerColo-rectal CancerCervical CancerBreast Cancer
Interventions
DRUG

Checkpoint inhibitor (CPI) such as Pembrolizumab plus chemotherapy

vein, artery, or intra-tumor infusion of checkpoint inhibitor (CPI) such as Pembrolizumab and/or Ipilimumab, plus chemotherapy to destroy cancer cells and release tumor antigen for improving CPI therapeutic efficacy.

Trial Locations (1)

51260

RECRUITING

The Second Affiliated Hospital of Guangzhou Medical University, Guanzhou

All Listed Sponsors
lead

Second Affiliated Hospital of Guangzhou Medical University

OTHER